Detalles de la búsqueda
1.
Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults.
Sci Rep
; 14(1): 7709, 2024 04 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38565882
2.
A prospective, multicentre, cohort study to assess the incidence of dengue illness in households from selected communities in Brazil (2014-2018).
Int J Infect Dis
; 108: 443-453, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33894353
3.
Duration of post-vaccination humoral immunity against yellow fever in children.
Vaccine
; 37(48): 7147-7154, 2019 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31590934
4.
Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
Front Immunol
; 10: 2433, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31695694
5.
Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Front Immunol
; 10: 2192, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31616412
6.
Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
Front Immunol
; 10: 1211, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31293563
7.
Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study.
Vaccine
; 36(28): 4112-4117, 2018 06 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29784469
8.
Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
J Immunol Methods
; 448: 9-20, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28514646
Resultados
1 -
8
de 8
1
Próxima >
>>